Temasek Holdings Private Ltd continued to hold its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,830,516 shares of the biopharmaceutical company’s stock at the end of the fourth quarter. Gilead Sciences accounts for about 7.9% of Temasek Holdings Private Ltd’s portfolio, making the stock its 3rd largest position. Temasek Holdings Private Ltd owned approximately 1.06% of Gilead Sciences worth $990,403,000 as of its most recent SEC filing.
A number of other institutional investors have also recently modified their holdings of GILD. State Street Corp boosted its position in shares of Gilead Sciences by 4.5% in the fourth quarter. State Street Corp now owns 60,448,831 shares of the biopharmaceutical company’s stock valued at $4,328,739,000 after buying an additional 2,587,072 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Gilead Sciences by 0.6% in the third quarter. Bank of New York Mellon Corp now owns 26,786,930 shares of the biopharmaceutical company’s stock valued at $2,119,382,000 after buying an additional 169,701 shares in the last quarter. BlackRock Fund Advisors boosted its position in Gilead Sciences by 6.8% in the third quarter. BlackRock Fund Advisors now owns 26,032,555 shares of the biopharmaceutical company’s stock worth $2,059,696,000 after buying an additional 1,663,268 shares during the period. Parnassus Investments CA boosted its position in Gilead Sciences by 27.5% in the third quarter. Parnassus Investments CA now owns 10,790,358 shares of the biopharmaceutical company’s stock worth $853,733,000 after buying an additional 2,329,874 shares during the period. Finally, Boston Partners boosted its position in Gilead Sciences by 51.7% in the third quarter. Boston Partners now owns 9,855,682 shares of the biopharmaceutical company’s stock worth $779,781,000 after buying an additional 3,358,289 shares during the period. 74.19% of the stock is owned by hedge funds and other institutional investors.
Gilead Sciences, Inc. (NASDAQ:GILD) traded down 0.86% during mid-day trading on Friday, hitting $65.93. The stock had a trading volume of 7,241,809 shares. The company has a 50-day moving average price of $67.57 and a 200 day moving average price of $71.70. Gilead Sciences, Inc. has a 1-year low of $65.38 and a 1-year high of $103.10. The company has a market cap of $86.17 billion, a P/E ratio of 6.63 and a beta of 1.11.
The firm also recently declared a quarterly dividend, which was paid on Thursday, March 30th. Shareholders of record on Thursday, March 16th were given a dividend of $0.52 per share. The ex-dividend date of this dividend was Tuesday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.47. This represents a $2.08 annualized dividend and a yield of 3.15%. Gilead Sciences’s payout ratio is 18.91%.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://transcriptdaily.com/2017/04/22/temasek-holdings-private-ltd-has-990403000-stake-in-gilead-sciences-inc-gild.html.
GILD has been the subject of a number of analyst reports. William Blair reissued an “outperform” rating on shares of Gilead Sciences in a report on Saturday, January 28th. Cowen and Company set a $100.00 price objective on Gilead Sciences and gave the company a “buy” rating in a research report on Wednesday, January 18th. Zacks Investment Research downgraded Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Monday, February 13th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $82.00 price objective on shares of Gilead Sciences in a research report on Thursday, April 6th. Finally, Goldman Sachs Group Inc reaffirmed a “hold” rating and issued a $81.00 price objective on shares of Gilead Sciences in a research report on Friday, January 13th. Eleven research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and two have issued a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $83.86.
In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction dated Monday, April 3rd. The shares were sold at an average price of $67.18, for a total transaction of $4,926,510.94. Following the sale, the insider now directly owns 3,199,969 shares of the company’s stock, valued at approximately $214,973,917.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Gregg H. Alton sold 5,000 shares of the business’s stock in a transaction dated Thursday, March 30th. The stock was sold at an average price of $67.48, for a total transaction of $337,400.00. Following the sale, the executive vice president now directly owns 117,988 shares in the company, valued at $7,961,830.24. The disclosure for this sale can be found here. Insiders own 1.40% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
